Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’
Clinical Oncology · 2026-08 · 56 · 104199
DOI: 10.1016/j.clon.2026.104199 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical Oncology, 2026-08. Verfasst von M Tao. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Clinical Medical College of Zhejiang Chinese Medical University, No. 548 Binwen Road,…. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Zhejiang Chinese Medical University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The First Clinical Medical College of Zhejiang Chinese Medical University, No. 548 Binwen Road, Binjiang District, Hangzhou, Zhejiang, 310053, China. Electronic addr…
Förderung
- Zhejiang Chinese Medical University
Zitieren
APA
Tao, M. (2026). Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’. Clinical Oncology, 56, 104199. https://doi.org/10.1016/j.clon.2026.104199
Vancouver
Tao M. Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’. Clinical Oncology. 2026;56:104199. doi:10.1016/j.clon.2026.104199
BibTeX
@article{Tao2026,
author = {Tao, M},
title = {Comment on ‘Clinical and Pathological Characteristics of Stage IV SMARCA4-Deficient Lung Cancer and the Efficacy of Immune Checkpoint Inhibitors’},
journal = {Clinical Oncology},
year = {2026},
volume = {56},
pages = {104199},
doi = {10.1016/j.clon.2026.104199}
}
EUVIMED